Oxytocin therapy for core symptoms in autism spectrum disorder: An updated meta-analysis of randomized controlled trials / Yue WANG in Research in Autism Spectrum Disorders, 64 (August 2019)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 64 (August 2019) . - p.63-75 Titre : Oxytocin therapy for core symptoms in autism spectrum disorder: An updated meta-analysis of randomized controlled trials Type de document : Texte imprimé et/ou numérique Auteurs : Yue WANG, Auteur ; Meng-Jie WANG, Auteur ; Ying RONG, Auteur ; Hui-Zhong HE, Auteur ; Chang-Jiang YANG, Auteur Article en page(s) : p.63-75 Langues : Anglais (eng) Mots-clés : Oxytocin  Autism spectrum disorder  Social function  Repetitive behaviors  Meta-analysis  Randomized controlled trials Index. décimale : PER Périodiques Résumé : Background Evidence of oxytocin for treating core symptoms in autism spectrum disorder (ASD) across development remains mixed and establishing its role is critical for guiding therapy. Aim The current paper is aimed to include new studies and provide a stricter and updated meta-analysis to assess the oxytocin's effects on core symptoms in ASD. Method Computerized search was conducted in PubMed, EMBASE, Cochrane Library, PsycINFO, Web of Science Database and references in reviews from the earliest date available to September 2018. Randomized controlled trials (RCTs) were identified which evaluated the effectiveness of oxytocin on at least one of two domains in patients with ASD, namely social function and repetitive behaviors. Standardized mean difference (SMD) and 95% confidence intervals (CIs) were calculated, and heterogeneity was assessed using the I2 test. Results Sixteen studies comprising 520 individuals with ASD were included in this meta-analysis. Results suggested that oxytocin had a small and non-significant effect on social function [SMD?=?0.03, 95% CI (?0.19, 0.25), p?=?0.781] and repetitive behaviors [SMD?=?0.01, 95% CI (?0.26, 0.27), p?=?0.952] compared with placebo. Studies included had a low heterogeneity (I2?=?46.4%, p?=?0.025 in social function; I2?=?37.0%, p?=?0.123 in repetitive behaviors). Conclusions The current meta-analysis demonstrated that oxytocin had a small and non-significant effect on core symptoms in ASD population. With the limited number of included studies, more large-scale, rigorously and multi-site RCTs are needed to confirm the effectiveness of oxytocin as a treatment of ASD to acquire more convincing conclusions in the future. En ligne : https://doi.org/10.1016/j.rasd.2019.03.007 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=399 [article] Oxytocin therapy for core symptoms in autism spectrum disorder: An updated meta-analysis of randomized controlled trials [Texte imprimé et/ou numérique] / Yue WANG, Auteur ; Meng-Jie WANG, Auteur ; Ying RONG, Auteur ; Hui-Zhong HE, Auteur ; Chang-Jiang YANG, Auteur . - p.63-75. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 64 (August 2019) . - p.63-75 Mots-clés : Oxytocin  Autism spectrum disorder  Social function  Repetitive behaviors  Meta-analysis  Randomized controlled trials Index. décimale : PER Périodiques Résumé : Background Evidence of oxytocin for treating core symptoms in autism spectrum disorder (ASD) across development remains mixed and establishing its role is critical for guiding therapy. Aim The current paper is aimed to include new studies and provide a stricter and updated meta-analysis to assess the oxytocin's effects on core symptoms in ASD. Method Computerized search was conducted in PubMed, EMBASE, Cochrane Library, PsycINFO, Web of Science Database and references in reviews from the earliest date available to September 2018. Randomized controlled trials (RCTs) were identified which evaluated the effectiveness of oxytocin on at least one of two domains in patients with ASD, namely social function and repetitive behaviors. Standardized mean difference (SMD) and 95% confidence intervals (CIs) were calculated, and heterogeneity was assessed using the I2 test. Results Sixteen studies comprising 520 individuals with ASD were included in this meta-analysis. Results suggested that oxytocin had a small and non-significant effect on social function [SMD?=?0.03, 95% CI (?0.19, 0.25), p?=?0.781] and repetitive behaviors [SMD?=?0.01, 95% CI (?0.26, 0.27), p?=?0.952] compared with placebo. Studies included had a low heterogeneity (I2?=?46.4%, p?=?0.025 in social function; I2?=?37.0%, p?=?0.123 in repetitive behaviors). Conclusions The current meta-analysis demonstrated that oxytocin had a small and non-significant effect on core symptoms in ASD population. With the limited number of included studies, more large-scale, rigorously and multi-site RCTs are needed to confirm the effectiveness of oxytocin as a treatment of ASD to acquire more convincing conclusions in the future. En ligne : https://doi.org/10.1016/j.rasd.2019.03.007 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=399

Prevalence of attention-deficit/hyperactivity disorder in individuals with autism spectrum disorder: A meta-analysis / Ying RONG in Research in Autism Spectrum Disorders, 83 (May 2021)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 83 (May 2021) . - 101759 Titre : Prevalence of attention-deficit/hyperactivity disorder in individuals with autism spectrum disorder: A meta-analysis Type de document : Texte imprimé et/ou numérique Auteurs : Ying RONG, Auteur ; Chang-Jiang YANG, Auteur ; Ye JIN, Auteur ; Yue WANG, Auteur Article en page(s) : 101759 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Attention-deficit/hyperactivity disorder  Current prevalence  Lifetime prevalence  Meta-analysis Index. décimale : PER Périodiques Résumé : Background Comorbidity with attention-deficit/hyperactivity disorder (ADHD) is very common in autism spectrum disorder (ASD), worsening the developmental trajectory of ASD. The reported rates of ADHD in ASD vary widely. However, no meta-analysis has been conducted specifically to assess both the current and lifetime prevalence of ADHD in ASD. This study aims to fill in this gap. Method We searched the Web of Science, PubMed, PsycINFO, CINAHL, and Embase databases for eligible articles published between January 1, 2000, and September 5, 2020. The risk of bias tool was used to assess the studies’ quality. Overall pooled estimates of the current and lifetime prevalence of ADHD in ASD were obtained using random-effects models. Study heterogeneity was examined by Q and I2 statistics. Findings A total of 63 articles were eventually included, of which 56 studies reported the current prevalence, and 13 studies reported the lifetime prevalence. The results revealed that the pooled current and lifetime prevalence rates of ADHD among ASD were 38.5 % (95 % CI 34.0–43.2) and 40.2 % (95 % CI 34.9–45.7), respectively. Our study also confirmed that age, intellectual disability, recruitment settings, and diagnostic criteria significantly influenced the current prevalence of ADHD in ASD. Conclusion ASD has considerable high current or lifetime prevalence rates of co-occurring ADHD. The findings demonstrate that clinicians should consider the high prevalence of ADHD in ASD and especially stay alert to possible ADHD diagnoses in school-age children and adolescents with ASD. Medical institutions should improve the assessment and tracking system of ADHD comorbidity in ASD and maximize the diagnostic accuracy for better treatment. En ligne : https://doi.org/10.1016/j.rasd.2021.101759 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=446 [article] Prevalence of attention-deficit/hyperactivity disorder in individuals with autism spectrum disorder: A meta-analysis [Texte imprimé et/ou numérique] / Ying RONG, Auteur ; Chang-Jiang YANG, Auteur ; Ye JIN, Auteur ; Yue WANG, Auteur . - 101759. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 83 (May 2021) . - 101759 Mots-clés : Autism spectrum disorder  Attention-deficit/hyperactivity disorder  Current prevalence  Lifetime prevalence  Meta-analysis Index. décimale : PER Périodiques Résumé : Background Comorbidity with attention-deficit/hyperactivity disorder (ADHD) is very common in autism spectrum disorder (ASD), worsening the developmental trajectory of ASD. The reported rates of ADHD in ASD vary widely. However, no meta-analysis has been conducted specifically to assess both the current and lifetime prevalence of ADHD in ASD. This study aims to fill in this gap. Method We searched the Web of Science, PubMed, PsycINFO, CINAHL, and Embase databases for eligible articles published between January 1, 2000, and September 5, 2020. The risk of bias tool was used to assess the studies’ quality. Overall pooled estimates of the current and lifetime prevalence of ADHD in ASD were obtained using random-effects models. Study heterogeneity was examined by Q and I2 statistics. Findings A total of 63 articles were eventually included, of which 56 studies reported the current prevalence, and 13 studies reported the lifetime prevalence. The results revealed that the pooled current and lifetime prevalence rates of ADHD among ASD were 38.5 % (95 % CI 34.0–43.2) and 40.2 % (95 % CI 34.9–45.7), respectively. Our study also confirmed that age, intellectual disability, recruitment settings, and diagnostic criteria significantly influenced the current prevalence of ADHD in ASD. Conclusion ASD has considerable high current or lifetime prevalence rates of co-occurring ADHD. The findings demonstrate that clinicians should consider the high prevalence of ADHD in ASD and especially stay alert to possible ADHD diagnoses in school-age children and adolescents with ASD. Medical institutions should improve the assessment and tracking system of ADHD comorbidity in ASD and maximize the diagnostic accuracy for better treatment. En ligne : https://doi.org/10.1016/j.rasd.2021.101759 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=446

---

1 (1 - 2 / 2)